Clinical Research

Government-funded program wants better AI for managing heart failure in the US
The long-term goal is to bring 24-7 cardiac care to every American, even those living in counties with no cardiologists.
Acoramidis bests tafamidis in head-to-head comparison of ATTR-CM drugs
Acoramidis was associated with a 43% lower risk of diuretic intensification and a 34% lower risk of clinical worsening overall.
TAVR timing: Waiting more than 6 months may hurt survival odds
When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
European Society of Cardiology joins effort to improve access to heart data
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
5 practice-changing trials from ESC Congress 2026
Damodhar Suresh, MD, spoke to Cardiovascular Business about some of the biggest studies presented during the annual ESC conference in Munich, Germany.

Early TAVR for asymptomatic severe AS cuts costs, improves outcomes

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

Winning cash for taking blood pressure meds increases compliance

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

VahatiCor's investigational A-Flux Reducer System helps increase perfusion by restricting the venous flow in the coronary sinus.

Device to treat coronary microvascular disease rakes in $23 million in financing

With no treatments available that directly improve INOCA, this breakthrough device offers hope.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Drinking coffee may reduce risk of recurrent AFib

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

AI-enabled coronary plaque quantification outperforms traditional risk scores

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.

Illustration showing how procizumab captures circulating dipeptidyl peptidase 3 (cDPP3) to block this key molecular driver of shock. Illustrations courtesy of 4TEEN4

$64M raised for new cardiogenic shock drug—research already underway

Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.

Coronary calcium may predict a patient's risk of dying from noncardiac conditions

Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.

Around the web

Radiology Business

Imaging artificial intelligence vendor Elucid raises $55M

Radiology Business

Cardiac CT's expanding role gives radiologists new opportunities

Clinical Research

Government-funded program wants better AI for managing heart failure in the US

Acoramidis bests tafamidis in head-to-head comparison of ATTR-CM drugs

TAVR timing: Waiting more than 6 months may hurt survival odds

European Society of Cardiology joins effort to improve access to heart data

5 practice-changing trials from ESC Congress 2026

Around the web